Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Statin Therapy for Primary Prevention of Atrial Fibrillation: Guided by $CHADS_2/CHA_2DS_2VASc$ Score

  • Hung, Chen-Ying (Cardiovascular Center, Taichung Veterans General Hospital) ;
  • Hsieh, Yu-Cheng (Cardiovascular Center, Taichung Veterans General Hospital) ;
  • Huang, Jin-Long (Cardiovascular Center, Taichung Veterans General Hospital) ;
  • Lin, Ching-Heng (Department of Medical Research, Taichung Veterans General Hospital) ;
  • Wu, Tsu-Juey (Cardiovascular Center, Taichung Veterans General Hospital)
  • Published : 2014.04.30
⟨ Previous Next ⟩

Abstract

Atrial fibrillation (AF) is the most common arrhythmia and is associated with increased cardiovascular morbidity and mortality. The anti-arrhythmic effect of statins on AF prevention appears to be highly significant in most clinical studies. However, some discrepancies do exist among different clinical studies. Different clinical settings and types of stains used may explain these differences between trials. The $CHADS_2$ and $CHA_2DS_2VASc$ scoring systems have been used for stroke risk stratification in AF patients. The recent study suggested that these scores can also be used to guide statin therapy for AF prevention. Patients with higher scores had a higher risk of developing AF and gained more benefits from statins therapy than those with lower scores. This review article focused on the ability of these scores to predict AF prevention by statins.

Keywords

References

  1. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158:229-34. https://doi.org/10.1001/archinte.158.3.229
  2. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009;54:2023-31. https://doi.org/10.1016/j.jacc.2009.08.020
  3. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84. https://doi.org/10.1016/S0002-9343(99)80348-9
  4. Chen PS, Athill CA, Wu TJ, Ikeda T, Ong JJ, Karagueuzian HS. Mechanisms of atrial fibrillation and flutter and implications for management. Am J Cardiol 1999;84(9A):125R-30R.
  5. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354. https://doi.org/10.1161/CIRCULATIONAHA.106.177292
  6. Macfarlane PW, Murray H, Sattar N, et al. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace 2011;13:634-9. https://doi.org/10.1093/europace/eur016
  7. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: populationbased estimates. Am J Cardiol 1998;82(8A):2N-9N. https://doi.org/10.1016/S0002-9149(98)00583-9
  8. Sandhu RK, Kurth T, Conen D, Cook NR, Ridker PM, Albert CM. Relation of renal function to risk for incident atrial fibrillation in women. Am J Cardiol 2012;109:538-42. https://doi.org/10.1016/j.amjcard.2011.10.006
  9. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25. https://doi.org/10.1161/CIRCULATIONAHA.105.595140
  10. Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Do statins have an antiarrhythmic activity? Cardiovasc Res 2007;75:10-20. https://doi.org/10.1016/j.cardiores.2007.02.029
  11. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011;13:308-28. https://doi.org/10.1093/europace/eur002
  12. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a metaanalysis of randomized controlled trials. J Am Coll Cardiol 2008;51:828-35. https://doi.org/10.1016/j.jacc.2007.09.063
  13. Fang WT, Li HJ, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol 2012;74:744-56. https://doi.org/10.1111/j.1365-2125.2012.04258.x
  14. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008;126:160-70. https://doi.org/10.1016/j.ijcard.2007.07.137
  15. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429. https://doi.org/10.1093/eurheartj/ehq278
  16. Komatsu T, Tachibana H, Sato Y, Ozawa M, Kunugita F, Nakamura M. Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation: comparison between atorvastatin and pravastatin. Int Heart J 2011;52:359-65. https://doi.org/10.1536/ihj.52.359
  17. Pellegrini CN, Vittinghoff E, Lin F, Hulley SB, Marcus GM. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. Heart 2009;95:704-8. https://doi.org/10.1136/hrt.2008.154054
  18. Pena JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 2012;33:531-7. https://doi.org/10.1093/eurheartj/ehr460
  19. Bang CN, Gislason GH, Greve AM, Torp-Pedersen C, Kober L, Wachtell K. Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study. Eur J Prev Cardiol 2014;21:330-8. https://doi.org/10.1177/2047487312462804
  20. Rahimi K, Emberson J, McGale P, et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011;342:d1250. https://doi.org/10.1136/bmj.d1250
  21. Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol 2013;28:7-18. https://doi.org/10.1097/HCO.0b013e32835b0956
  22. Wang Z, Zhang Y, Gao M, et al. Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Pharmacotherapy 2011;31:1051-62. https://doi.org/10.1592/phco.31.11.1051
  23. Bang CN, Greve AM, Abdulla J, Kober L, Gislason GH, Wachtell K. The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: a systematic review and meta-analysis. Int J Cardiol 2013;167:624-30. https://doi.org/10.1016/j.ijcard.2012.08.056
  24. Huang SS, Chan WL, Leu HB, Huang PH, Chen JW, Lin SJ. Association between CHADS2 score and the preventive effect of statin therapy on new-onset atrial fibrillation in patients with acute myocardial infarction. PLoS One 2013;8:e74709. https://doi.org/10.1371/journal.pone.0074709
  25. Chao TF, Liu CJ, Chen SJ, et al. CHADS2 score and risk of new-onset atrial fibrillation: a nationwide cohort study in Taiwan. Int J Cardiol 2013;168:1360-3. https://doi.org/10.1016/j.ijcard.2012.12.011
  26. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:1144-50. https://doi.org/10.1161/CIR.0b013e31820f14c0
  27. Chao TF, Cheng CC, Lin WS, et al. Associations among the CHADS(2) score, atrial substrate properties, and outcome of catheter ablation in patients with paroxysmal atrial fibrillation. Heart Rhythm 2011;8:1155-9. https://doi.org/10.1016/j.hrthm.2011.03.016
  28. Park JH, Joung B, Son NH, et al. The electroanatomical remodelling of the left atrium is related to CHADS2/CHA2DS2VASc score and events of stroke in patients with atrial fibrillation. Europace 2011;13:1541-9. https://doi.org/10.1093/europace/eur135
  29. Hung CY, Lin CH, Loh el-W, Ting CT, Wu TJ. CHADS(2) score, statin therapy, and risks of atrial fibrillation. Am J Med 2013;126:133-40. https://doi.org/10.1016/j.amjmed.2012.06.027
  30. Hung CY, Lin CH, Wang KY, et al. Dosage of statin, cardiovascular comorbidities, and risk of atrial fibrillation: a nationwide population-based cohort study. Int J Cardiol 2013;168:1131-6. https://doi.org/10.1016/j.ijcard.2012.11.087
  31. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 2005;13:181-93. https://doi.org/10.1007/s10840-005-2362-y
  32. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit 2003;9:RA225-9.
  33. Page RL, Roden DM. Drug therapy for atrial fibrillation: where do we go from here? Nat Rev Drug Discov 2005;4:899-910. https://doi.org/10.1038/nrd1876
  34. Murray KT, Mace LC, Yang Z. Nonantiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm 2007;4(3 Suppl):S88-90. https://doi.org/10.1016/j.hrthm.2006.12.027
  35. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007;50:2021-8. https://doi.org/10.1016/j.jacc.2007.06.054
  36. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083-92. https://doi.org/10.1093/eurheartj/ehi350
  37. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007;49:1642-8. https://doi.org/10.1016/j.jacc.2006.12.042
  38. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10. https://doi.org/10.1161/01.CIR.0000103131.70301.4F
  39. Goonasekara CL, Balse E, Hatem S, Steele DF, Fedida D. Cholesterol and cardiac arrhythmias. Expert Rev Cardiovasc Ther 2010;8:965-79. https://doi.org/10.1586/erc.10.79
  40. Calo L, Martino A, Sciarra L, et al. Upstream effect for atrial fibrillation: still a dilemma? Pacing Clin Electrophysiol 2011;34:111-28. https://doi.org/10.1111/j.1540-8159.2010.02942.x
  41. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004;62:105-11. https://doi.org/10.1016/j.cardiores.2004.01.018
  42. Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble Pselectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med 2000;48:183-9.
  43. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000;80:1095-100. https://doi.org/10.1038/labinvest.3780115
  44. Liang YJ, Shyu KG, Wang BW, Lai LP. Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Cardiology 2008;110:182-90. https://doi.org/10.1159/000111928
  45. Savelieva I, Kourliouros A, Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol 2010;381:1-13.
  46. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999;353:118-9. https://doi.org/10.1016/S0140-6736(05)76154-7
  47. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447-52. https://doi.org/10.1161/01.CIR.0000029743.68247.31
  48. Naji F, Sabovic M. The current role of statin therapy in the treatment of atrial fibrillation. Cardiovasc Hematol Agents Med Chem 2013;11:9-13. https://doi.org/10.2174/1871525711311010004
  49. Caorsi C, Pineda F, Munoz C. Pravastatin immunomodulates IL-6 and Creactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass. Eur Cytokine Netw 2008;19:99-103.
  50. Chello M, Patti G, Candura D, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006;34:660-7. https://doi.org/10.1097/01.CCM.0000201407.89977.EA
  51. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005;150:1064.
  52. Mannacio VA, Iorio D, De Amicis V, Di Lello F, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg 2008;136:1541-8. https://doi.org/10.1016/j.jtcvs.2008.06.038
  53. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006;97:1490-3. https://doi.org/10.1016/j.amjcard.2005.11.082
  54. Crandall MA, Horne BD, Day JD, et al. Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently. Pacing Clin Electrophysiol 2009;32:648-52. https://doi.org/10.1111/j.1540-8159.2009.02339.x
  55. Maehama T, Okura H, Imai K, et al. Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation. Am J Cardiol 2010;106:535-8. https://doi.org/10.1016/j.amjcard.2010.03.067
  56. Ishii S, Karlamangla AS, Bote M, et al. Gender, obesity and repeated elevation of C-reactive protein: data from the CARDIA cohort. PLoS One 2012;7:e36062. https://doi.org/10.1371/journal.pone.0036062
  57. Amer MS, Elawam AE, Khater MS, Omar OH, Mabrouk RA, Taha HM. Association of high-sensitivity C-reactive protein with carotid artery intima-media thickness in hypertensive older adults. J Am Soc Hypertens 2011;5:395-400. https://doi.org/10.1016/j.jash.2011.03.004
  58. Wang TJ, Larson MG, Levy D, et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation 2002;106:1189-91. https://doi.org/10.1161/01.CIR.0000032135.98011.C4
  59. Hung CY, Hsieh YC, Wang KY, et al. Efficacy of different statins for primary prevention of atrial fibrillation in male and female patients: a nationwide population-based cohort study. Int J Cardiol 2013;168:4367-9. https://doi.org/10.1016/j.ijcard.2013.05.057
  60. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012;30:623-30. https://doi.org/10.1200/JCO.2011.36.0917
  61. Lee CW, Kang SJ, Ahn JM, et al. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial). Am J Cardiol 2012;109:1700-4. https://doi.org/10.1016/j.amjcard.2012.01.399
  62. Sironi L, Gianazza E, Gelosa P, et al. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol 2005;25:598-603. https://doi.org/10.1161/01.ATV.0000157145.98200.55
  63. Li J, Sun YM, Wang LF, Li ZQ, Pan W, Cao HY. Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. Clin Cardiol 2010;33:222-7. https://doi.org/10.1002/clc.20724
  64. Su Y, Xu Y, Sun YM, et al. Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol 2010;55:21-5. https://doi.org/10.1097/FJC.0b013e3181bfb1df
  65. Tonstad S, Sandvik E, Larsen PG, Thelle D. Gender differences in the prevalence and determinants of the metabolic syndrome in screened subjects at risk for coronary heart disease. Metab Syndr Relat Disord 2007;5:174-82. https://doi.org/10.1089/met.2006.0037
  66. Djindjic B, Rankovic G, Zivic M, Savic T, Spasic M, Bubanj M. [Gender difference in hipolipemic and anti-inflammatory effects of statins in diabetics with coronary artery disease]. Vojnosanit Pregl 2009;66:966-72. https://doi.org/10.2298/VSP0912966D
  67. Nakhjavani M, Morteza A, Meysamie A, et al. Serum heat shock protein 70 and oxidized LDL in patients with type 2 diabetes: does sex matter? Cell Stress Chaperones 2011;16:195-201. https://doi.org/10.1007/s12192-010-0232-8
  68. Dantas AP, Franco Mdo C, Silva-Antonialli MM, et al. Gender differences in superoxide generation in microvessels of hypertensive rats: role of NAD(P)H-oxidase. Cardiovasc Res 2004;61:22-9. https://doi.org/10.1016/j.cardiores.2003.10.010

Cited by

  1. Addition of B-Type Natriuretic Peptide to Existing Clinical Risk Scores Enhances Identification of Patients at Risk for Atrial Fibrillation Recurrence After Pulmonary Vein Isolation vol.14, pp.4, 2014, https://doi.org/10.1097/hpc.0000000000000060
  2. Age and CHADS 2 Score Predict the Effectiveness of Renin-Angiotensin System Blockers on Primary Prevention of Atrial Fibrillation vol.5, pp.None, 2014, https://doi.org/10.1038/srep11442
  3. Statin Adherence Is Associated With Reduced Recurrent Stroke Risk in Patients With or Without Atrial Fibrillation vol.48, pp.7, 2014, https://doi.org/10.1161/strokeaha.117.017343